Press Releases

11.24.2021

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

11.24.2021

Pfizer Announces Topline Results from Phase 2b Trial of Vupanorsen in Statin-treated Participants with Dyslipidemia

11.22.2021

Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age

11.19.2021

Arvinas And Pfizer Announce Updated Phase 1 Dose Escalation Data For ARV-471 To Be Presented In Spotlight Poster Session At 2021 San Antonio Breast Cancer Symposium

11.19.2021

Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older

11.18.2021

Pfizer’s XELJANZ® (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis

11.18.2021

Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19

11.17.2021

Pfizer Completes Acquisition of Trillium Therapeutics

11.17.2021

Pfizer Announces Retirement of Chief Financial Officer Frank D’Amelio

11.16.2021

Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate

11.16.2021

Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries

11.11.2021

Zipline, Pfizer and BioNTech Collaboration Paves the Way for Automated, On-Demand Delivery of First mRNA COVID-19 Vaccines in Ghana